Oslo, Norway, November 15, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced its unaudited financial
results for the third quarter of 2023.
 
The financial report can be accessed in the Investors section of the Company's
website: https://nykode.com/investors/financial-reports-and-presentations 

The Company will host a webcast presentation at 4 p.m. CET / 10 a.m. ET. A live
and archived webcast of the presentation can be accessed in the Investors
section of the Company's website and on the following link:
https://event.webcasts.com/starthere.jsp?ei=1640257&tp_key=2a6664ef92


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies with a focus on the
treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells (APC), which have been
shown to induce broad, strong, and long-lasting antigen specific immune
responses which correlates with clinical responses in cancer.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of HPV16 induced malignancies which demonstrated favorable safety and
efficacy results from its Phase 2 trial for the treatment of cervical cancer